Dr. Doug Chapnick is an expert in transgenic engineering of human cells. He led technology R&D in the DARPA funded ‘Rapid Threat Assessment (RTA)’ project at the University of Colorado, Boulder, and founded BioLoomics to apply advances in synthetic biology from the RTA project to enable directed evolution of peptide-antibody chimeras in human cells. During the 7-year RTA project, Doug accumulated a wealth of technical expertise in protein and cell engineering that revealed new insights into the biophysics of cell membranes. Such interactions are widely ignored by drug developers but can drive the spatial fate of antibodies to specific organelles, opening the door to engineer antibodies with spatial programs to increase the molecular toolbox in pharma. At BioLoomics, Doug has led the technical development of hardware, software, synthetic biology and protein engineering in addition to successfully raising $10M in seed funds from leading venture capital funds.